Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting | New England Journal
of Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

New insights into the pathophysiology of chemotherapy-induced nausea and vomiting, a
better understanding of patients at risk, and the availability of new antiemetic agents have all …

Tumour innervation is associated with worse patient outcomes in multiple cancers,, which
suggests that it may regulate metastasis. Here we observed that highly metastatic mouse …

Despite the relevant progress achieved in the last 20 years, vomiting and, especially,
nausea, continue to be two of the most distressing side-effects of cancer chemotherapy. In …

The treatment of advanced non-small cell lung cancer (NSCLC) may be changing, but the
cisplatin-based doublet remains the foundation of treatment for the majority of patients with …

Purpose To update the 1999 American Society of Clinical Oncology guideline for
antiemetics in oncology. Update Methodology The Update Committee completed a review …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Antiemesis
address all aspects of management for chemotherapy-induced nausea and vomiting. These …

About half of all cancer patients show a syndrome of cachexia, characterized by anorexia
and loss of adipose tissue and skeletal muscle mass. Cachexia can have a profound impact …

Patients with cancer should appropriately receive antiemetic therapies against
chemotherapy-induced nausea and vomiting (CINV). Antiemetic guidelines play an …

Purpose This is the first study in which the NK1-receptor antagonist, aprepitant (APR), was
evaluated for the prevention of chemotherapy-induced nausea and vomiting (CINV) with …